Lantheus Holdings Inc
LNTH
查看详细走势图
67.175USD
-0.635-0.94%
收盘 01/27, 16:00（美东）报价延迟15分钟
4.45B总市值
27.27市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.94%
5天
+1.97%
1月
+0.70%
6月
-7.89%
今年开始到现在
+0.94%
1年
-31.67%
查看详细走势图
TradingKey Lantheus Holdings Inc股票评分
单位: USD 更新时间: 2026-01-26操作建议
Lantheus Holdings Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在医疗设备与耗材行业排名9/205位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价82.92。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Lantheus Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Lantheus Holdings Inc亮点
亮点风险
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
业绩高增长
公司营业收入稳步增长，连续3年增长64.04%
利润高增长
公司净利润处于行业前列，最新年度总收入1.53B美元
估值高估
公司最新PE估值27.53，处于3年历史高位
机构减仓
最新机构持股73.07M股，环比减少15.81%
HACAX持仓
明星投资者HACAX持仓，最新持仓市值32.60K
活跃度增加
近期活跃度增加，过去20天平均换手率1.29
分析师目标
根据
13
位分析师
买入
评级
82.923
目标均价
+22.83%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Lantheus Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Lantheus Holdings Inc简介
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
公司代码LNTH
公司Lantheus Holdings Inc
CEOMarkison (Brian A)
网址https://www.lantheus.com/
相关品种
-15.49%
-1.07%
-0.46%
+0.41%
-1.46%
-0.25%
-0.35%
-0.44%
+6.84%
-9.05%
-7.15%
-1.36%
-0.50%
+0.70%
-0.58%
-0.36%
+0.24%
+0.11%
+0.22%
+0.33%
